ROS1 and non-small cell lung carcinoma: Aside from point mutations in the structural domain of ROS1 and the activation of bypass signaling pathways, some unknown drug resistance mechanisms exist, such as lorlatinib resistance in patients with ROS1 fusion‐positive NSCLC.80